Literature DB >> 1886674

Prominent meningeal "tail sign" in a patient with a metastatic tumor.

M Senegor1.   

Abstract

A prominent enhancement of the dura adjacent to meningiomas has been described as being pathognomonic of these tumors. We describe a case where a classic meningeal "tail sign" was associated with an extra-axial metastatic tumor attached to the tentorium. There was no tumor invasion of the dura. We conclude that this sign is nonspecific and can be seen with dural-based tumors other than meningiomas.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1886674     DOI: 10.1097/00006123-199108000-00025

Source DB:  PubMed          Journal:  Neurosurgery        ISSN: 0148-396X            Impact factor:   4.654


  6 in total

1.  Intraosseous hemangioma of the skull with dural tail sign: radiologic features with pathologic correlation.

Authors:  Maria Politi; Bernd F M Romeike; Panagiotis Papanagiotou; Abdullah Nabhan; Tobias Struffert; Wolfgang Feiden; Wolfgang Reith
Journal:  AJNR Am J Neuroradiol       Date:  2005-09       Impact factor: 3.825

2.  Medulloblastoma presenting with tentorial "dural-tail" sign: is the "dural-tail" sign specific for meningioma?

Authors:  P W Detwiler; J S Henn; R W Porter; M T Lawton; W L White; R F Spetzler
Journal:  Skull Base Surg       Date:  1998

3.  Problems with the "dural tail" sign.

Authors:  S Gupta; R K Gupta; D Banerjee; R B Gujral
Journal:  Neuroradiology       Date:  1993       Impact factor: 2.804

4.  The dural tail of intracranial meningiomas on fluid-attenuated inversion-recovery images.

Authors:  T Takeguchi; H Miki; T Shimizu; K Kikuchi; T Mochizuki; S Ohue; T Ohnishi
Journal:  Neuroradiology       Date:  2004-01-28       Impact factor: 2.804

Review 5.  Extra-axial brain tumors.

Authors:  Antonios Drevelegas
Journal:  Eur Radiol       Date:  2004-12-31       Impact factor: 7.034

Review 6.  The Current State of Radiomics for Meningiomas: Promises and Challenges.

Authors:  Hao Gu; Xu Zhang; Paolo di Russo; Xiaochun Zhao; Tao Xu
Journal:  Front Oncol       Date:  2020-10-27       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.